drugset / Trial / NCT00722384
Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To establish the tolerability and preliminary efficacy of Cand5 by a single intravitreal injection in patients with wet age-related macular degeneration.
Timeline
- Start
- 2004-08
- Primary completion
- 2007-08
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bevasiranib | Unknown | 0.1 mg | Intravitreal |
| Subject | bevasiranib | Unknown | 0.33 mg | Intravitreal |
| Subject | bevasiranib | Unknown | 1 mg | Intravitreal |
| Subject | bevasiranib | Unknown | 1.5 mg | Intravitreal |
| Subject | bevasiranib | Unknown | 3 mg | Intravitreal |